Inhalatn Scieiences AB signed a new R&D contract worth 257,000 SEK for Inhalation Research Services (IRS) work for a returning, long-standing customer - a major branded generic pharma company. A long-standing customer of ISAB's research services and instruments is outsourcing research and development work worth 257,000 SEK to ISAB during a peak in their development activities. The work will be carried out using ISAB's flexible, multi-modular PreciseInhale aerosol generation system that enables precision dosing of a range of in vitro and in vivo exposure modules.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.34 SEK | +6.90% | -.--% | +7.43% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+7.43% | 6.08M | |
+12.85% | 227B | |
+13.88% | 192B | |
+18.39% | 136B | |
+28.78% | 108B | |
+1.67% | 64.07B | |
+18.24% | 52.1B | |
+7.04% | 51.87B | |
+10.83% | 44.33B | |
+5.94% | 36.75B |
- Stock Market
- Equities
- ISAB Stock
- News Inhalation Sciences Sweden AB
- Inhalation Sciences Signs R&D Order Worth 257,000 SEK with Major Generic Pharma Company